Du är här

2016-01-21

Basilea Pharmaceutica AG: GSK informs Basilea that it has elected not to continue its U.S. alitretinoin program

Basilea Pharmaceutica AG / GSK informs Basilea that it has elected not to
continue its U.S. alitretinoinprogram . Processed and transmitted by NASDAQ
OMX Corporate Solutions.The issuer is solely responsible for the content of
this announcement.
Basel, Switzerland, January 21, 2016

- GSK (GlaxoSmithKline) informed Basilea today that it has elected to
discontinue its U.S. alitretinoin program. Global rights to Toctino
(alitretinoin) were transferred to Stiefel, a GSK company, in July 2012.
Basilea has the option to re-acquire the U.S. alitretinoin rights. GSK
continues to commercialize Toctino in its current markets.

About Basilea

Basilea Pharmaceutica Ltd. is a biopharmaceutical company developing products
that address increasing resistance and non-response to current treatment
options in the therapeutic areas of bacterial infections, fungal infections
and cancer. The company uses the integrated research, development and
commercial operations of its subsidiary Basilea Pharmaceutica International
Ltd. to discover, develop and commercialize innovative pharmaceutical
products to meet the medical needs of patients with serious and potentially
life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in
Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN).
Additional information can be found at Basilea's websitewww.basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
performance or achievements of Basilea Pharmaceutica Ltd. to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is
providing this communication as of this date and does not undertake to update
any forward-looking statements contained herein as a result of new
information, future events or otherwise.

For further information, please contact:

-------------------------------------------------------------
| Media Relations Investor Relations |
| Peer Nils Schröder, PhD Barbara Zink, PhD, MBA |
| |
|Head Public Relations& Head Corporate Development |
|Corporate Communications |
|+41 61 606 1102 +41 61 606 1233 |
|media_relations@basilea.com investor_relations@basilea.com |
-------------------------------------------------------------
This press release can be downloaded fromwww.basilea.com.

Press release (PDF)
http://hugin.info/134390/R/1980584/725577.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Globenewswire

HUG#1980584

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.